Abiopharma

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

New Form 8-K - ASSEMBLY BIOSCIENCES, INC. Filed: 2025-08-08 AccNo: 0001193125-25-176138 Size: 186 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 10-Q - U S PHYSICAL THERAPY INC /NV Filed: 2025-08-08 AccNo: 0001140361-25-029744 Size: 12 MB

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

New Form 8-K - REVELATION BIOSCIENCES, INC. Filed: 2025-08-08 AccNo: 0000950170-25-105485 Size: 428 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - KALA BIO, Inc. Filed: 2025-08-08 AccNo: 0001558370-25-010853 Size: 9 MB

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Floridas Agency for Health Care Administration (AHCA)

New Form 8-K - KALA BIO, Inc. Filed: 2025-08-08 AccNo: 0001558370-25-010850 Size: 270 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form ARS - XWELL, Inc. Filed: 2025-08-08 AccNo: 0001104659-25-075471 Size: 1 MB

Vaxart CEO Issues Letter to Stockholders

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

New Form 10-Q - Green Planet Bio Engineering Co. Ltd. Filed: 2025-08-08 AccNo: 0001654954-25-009248 Size: 1 MB

New Form 8-K - Incannex Healthcare Inc. Filed: 2025-08-08 AccNo: 0001213900-25-073321 Size: 383 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits